However, despite the fact that cancer vaccines could effectively foster the host adaptive immune response against specific tumor epitopes, a low magnitude of CD8+ T cells and humoral agents was observed in clinical trials, which were ineffective in targeting tumor spread. The gene discussed is CD8A; the disease is neoplasm.